. Author manuscript; available in PMC: 2017 Aug 1.

Published in final edited form as: Acta Neuropathol. 2016 May 14;132(2):225–234. doi: 10.1007/s00401-016-1580-y

Table 2.

Association of Sex and APOE4 with CAA Score

		Sex and APOE4 in model ^c		Additionally adjusting for age, Braak stage and Thal stage ^c

Covariate	Subgroup	Effect (95% CI)	p-value ^d	Effect (95% CI)	p-value ^d
Male	All ^a	0.25 (0.10, 0.40)	<.001	0.27 (0.12, 0.42)	<.001
	APOE4− ^b	0.27 (0.03, 0.51)	0.027	0.29 (0.05, 0.53)	0.017
	APOE4+ ^b	0.24 (0.05, 0.43)	0.014	0.26 (0.06, 0.46)	0.010

APOE4+	All ^a	0.23 (0.08, 0.38)	0.003	0.22 (0.06, 0.37)	0.005
	Females ^b	0.24 (0.04, 0.44)	0.017	0.23 (0.03, 0.43)	0.024
	Males ^b	0.21 (−0.02, 0.45)	0.074	0.20 (−0.03, 0.43)	0.095

APOE4 allelic dose	All ^a	0.30 (0.20, 0.41)	<.001	0.30 (0.19, 0.40)	<.001
	Females ^b	0.30 (0.16, 0.44)	<.001	0.29 (0.15, 0.43)	<.001
	Males ^b	0.30 (0.15, 0.46)	<.001	0.31 (0.15, 0.46)	<.001

Results from models with no interaction terms.

Results from models with interaction of APOE4 and sex.

Age is included as a continuous variable, Braak stage as dichotomous (6 vs. <6), and Thal as dichotomous (5 vs. <5).

Wald p-value.